시장보고서

상품코드

1505891

신생혈관형 노인황반변성 : 시장 인사이트, 역학, 시장 예측(2034년)

Neovascular Age-related Macular Degeneration - Market Insight, Epidemiology, and Market Forecast - 2034

발행일: On demand Report | 리서치사:

DelveInsight | 페이지 정보: 영문 200 Pages | 배송안내 : 2-10일 (영업일 기준)

■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

샘플 요청 목록에 추가

신생혈관형 노인황반변성의 주요 7 시장(미국, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본)에 대해 조사분석했으며, 각 지역의 시장 규모, 현재의 치료법, 미충족 요구, 신약 등의 정보를 제공하고 있습니다.

역학의 주요 조사 결과
전제조건과 근거 : 주요 7 시장
역학 시나리오 : 주요 7 시장
- 주요 7 시장의 신생혈관형 노인황반변성 역학 시나리오(2020-2034년)
미국의 역학
- 미국의 신생혈관형 노인황반변성 역학 시나리오(2020-2034년)
유럽 5개국의 역학 : 국가별
- 독일의 역학
- 프랑스의 역학
- 이탈리아의 역학
- 스페인의 역학
- 영국의 역학
- 일본의 역학

제8장 치료 알고리즘, 현재의 치료, 의료 행위

신생혈관형 노인황반변성의 치료와 관리
신생혈관형 노인황반변성의 치료 알고리즘

제9장 미충족 요구

제10장 신생혈관형 노인황반변성 치료의 주요 평가항목

제11장 출시 제품

제12장 신치료법

제13장 신생혈관형 노인황반변성 : 주요 7 시장 분석

주요 조사 결과
주요 7 시장의 신생혈관형 노인황반변성 시장 규모
주요 7 시장의 신생혈관형 노인황반변성 시장 규모 : 치료법별

제14장 속성 분석

제15장 주요 7 시장 : 시장 전망

미국 : 시장 규모
- 미국의 신생혈관형 노인황반변성 전체 시장 규모
- 미국의 신생혈관형 노인황반변성 시장 규모 : 치료법별
유럽 5개국 : 시장 규모와 전망
독일 시장 규모
- 독일의 신생혈관형 노인황반변성 전체 시장 규모
- 독일의 신생혈관형 노인황반변성 시장 규모 : 치료법별
프랑스 시장 규모
이탈리아 시장 규모
스페인 시장 규모
영국 시장 규모
- 영국의 신생혈관형 노인황반변성 전체 시장 규모
- 영국의 신생혈관형 노인황반변성 시장 규모 : 치료법별
일본 시장 전망
- 일본 시장 규모

제16장 신생혈관형 노인황반변성 액세스와 보험 상환의 개요

제17장 KOL의 견해

제18장 시장 촉진요인

제19장 시장의 장벽

제20장 부록

제21장 DelveInsight의 서비스 내용

제22장 면책사항

제23장 DelveInsight 소개

KSA 24.07.09

DelveInsight's "Neovascular Age-related Macular Degeneration - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Neovascular Age-related Macular Degeneration, historical and forecasted epidemiology as well as the Neovascular Age-related Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Neovascular Age-related Macular Degeneration market report provides current treatment practices, emerging drugs, Neovascular Age-related Macular Degeneration market share of the individual therapies, current and forecasted Neovascular Age-related Macular Degeneration market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Neovascular Age-related Macular Degeneration treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2020-2034

Neovascular Age-related Macular Degeneration Disease Understanding and Treatment Algorithm

The DelveInsight Neovascular Age-related Macular Degeneration market report gives a thorough understanding of the Neovascular Age-related Macular Degeneration by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Neovascular Age-related Macular Degeneration.

Treatment

It covers the details of conventional and current medical therapies available in the Neovascular Age-related Macular Degeneration market for the treatment of the condition. It also provides Neovascular Age-related Macular Degeneration treatment algorithms and guidelines in the United States, Europe, and Japan.

Neovascular Age-related Macular Degeneration Epidemiology

The Neovascular Age-related Macular Degeneration epidemiology division provide insights about historical and current Neovascular Age-related Macular Degeneration patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Neovascular Age-related Macular Degeneration epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Neovascular Age-related Macular Degeneration Epidemiology

The epidemiology segment also provides the Neovascular Age-related Macular Degeneration epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Neovascular Age-related Macular Degeneration Drug Chapters

Drug chapter segment of the Neovascular Age-related Macular Degeneration report encloses the detailed analysis of Neovascular Age-related Macular Degeneration marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Neovascular Age-related Macular Degeneration clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Neovascular Age-related Macular Degeneration treatment.

Neovascular Age-related Macular Degeneration Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Neovascular Age-related Macular Degeneration treatment.

Neovascular Age-related Macular Degeneration Market Outlook

The Neovascular Age-related Macular Degeneration market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Neovascular Age-related Macular Degeneration market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Neovascular Age-related Macular Degeneration market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Neovascular Age-related Macular Degeneration market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Neovascular Age-related Macular Degeneration market in 7MM.

The United States Market Outlook

This section provides the total Neovascular Age-related Macular Degeneration market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Neovascular Age-related Macular Degeneration market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Neovascular Age-related Macular Degeneration market size and market size by therapies in Japan is also mentioned.

Neovascular Age-related Macular Degeneration Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Neovascular Age-related Macular Degeneration market or expected to get launched in the market during the study period 2020-2034. The analysis covers Neovascular Age-related Macular Degeneration market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Neovascular Age-related Macular Degeneration Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Neovascular Age-related Macular Degeneration key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Neovascular Age-related Macular Degeneration emerging therapies.

Reimbursement Scenario in Neovascular Age-related Macular Degeneration

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Neovascular Age-related Macular Degeneration domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Neovascular Age-related Macular Degeneration market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Neovascular Age-related Macular Degeneration Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

The report covers the descriptive overview of Neovascular Age-related Macular Degeneration, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Neovascular Age-related Macular Degeneration epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Neovascular Age-related Macular Degeneration are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Neovascular Age-related Macular Degeneration market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Neovascular Age-related Macular Degeneration market

Report Highlights:

In the coming years, Neovascular Age-related Macular Degeneration market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Neovascular Age-related Macular Degeneration R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Neovascular Age-related Macular Degeneration. Launch of emerging therapies will significantly impact the Neovascular Age-related Macular Degeneration market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Neovascular Age-related Macular Degeneration
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Neovascular Age-related Macular Degeneration Report Insights

Patient Population
Therapeutic Approaches
Neovascular Age-related Macular Degeneration Pipeline Analysis
Neovascular Age-related Macular Degeneration Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Neovascular Age-related Macular Degeneration Report Key Strengths

11 Years Forecast
7MM Coverage
Neovascular Age-related Macular Degeneration Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Neovascular Age-related Macular Degeneration Report Assessment

Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Questions:

Market Insights:

What was the Neovascular Age-related Macular Degeneration market share (%) distribution in 2020 and how it would look like in 2034?
What would be the Neovascular Age-related Macular Degeneration total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Neovascular Age-related Macular Degeneration market size during the forecast period (2024-2034)?
At what CAGR, the Neovascular Age-related Macular Degeneration market is expected to grow in 7MM during the forecast period (2020-2034)?
What would be the Neovascular Age-related Macular Degeneration market outlook across the 7MM during the forecast period (2020-2034)?
What would be the Neovascular Age-related Macular Degeneration market growth till 2032, and what will be the resultant market Size in the year 2034?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What is the disease risk, burden and unmet needs of the Neovascular Age-related Macular Degeneration?
What is the historical Neovascular Age-related Macular Degeneration patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Neovascular Age-related Macular Degeneration in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Neovascular Age-related Macular Degeneration?
Out of all 7MM countries, which country would have the highest prevalent population of Neovascular Age-related Macular Degeneration during the forecast period (2020-2034)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

What are the current options for the Neovascular Age-related Macular Degeneration treatment, along with the approved therapy?
What are the current treatment guidelines for the treatment of Neovascular Age-related Macular Degeneration in the USA, Europe, and Japan?
What are the Neovascular Age-related Macular Degeneration marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Neovascular Age-related Macular Degeneration?
How many therapies are developed by each company for Neovascular Age-related Macular Degeneration treatment?
How many are emerging therapies in mid-stage, and late stage of development for Neovascular Age-related Macular Degeneration treatment?
What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Neovascular Age-related Macular Degeneration therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Neovascular Age-related Macular Degeneration and their status?
What are the key designations that have been granted for the emerging therapies for Neovascular Age-related Macular Degeneration?
What are the global historical and forecasted market of Neovascular Age-related Macular Degeneration?

Reasons to buy:

The report will help in developing business strategies by understanding trends shaping and driving the Neovascular Age-related Macular Degeneration market
To understand the future market competition in the Neovascular Age-related Macular Degeneration market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Neovascular Age-related Macular Degeneration in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Neovascular Age-related Macular Degeneration market
To understand the future market competition in the Neovascular Age-related Macular Degeneration market

1. Key Insights

2. Executive Summary of Neovascular Age-related Macular Degeneration

3. Competitive Intelligence Analysis for Neovascular Age-related Macular Degeneration

4. Neovascular Age-related Macular Degeneration: Market Overview at a Glance

4.1. Neovascular Age-related Macular Degeneration Total Market Share (%) Distribution in 2020
4.2. Neovascular Age-related Macular Degeneration Total Market Share (%) Distribution in 2034

5. Neovascular Age-related Macular Degeneration: Disease Background and Overview

5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis

6. Patient Journey

7. Neovascular Age-related Macular Degeneration Epidemiology and Patient Population

7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
- 7.3.1. Neovascular Age-related Macular Degeneration Epidemiology Scenario in the 7MM (2020-2034)
7.4. United States Epidemiology
- 7.4.1. Neovascular Age-related Macular Degeneration Epidemiology Scenario in the United States (2020-2034)
7.5. EU-5 Country-wise Epidemiology
- 7.5.1. Germany Epidemiology
  - 7.5.1.1. Neovascular Age-related Macular Degeneration Epidemiology Scenario in Germany (2020-2034)
- 7.5.2. France Epidemiology
  - 7.5.2.1. Neovascular Age-related Macular Degeneration Epidemiology Scenario in France (2020-2034)
- 7.5.3. Italy Epidemiology
  - 7.5.3.1. Neovascular Age-related Macular Degeneration Epidemiology Scenario in Italy (2020-2034)
- 7.5.4. Spain Epidemiology
  - 7.5.4.1. Neovascular Age-related Macular Degeneration Epidemiology Scenario in Spain (2020-2034)
- 7.5.5. United Kingdom Epidemiology
  - 7.5.5.1. Neovascular Age-related Macular Degeneration Epidemiology Scenario in the United Kingdom (2020-2034)
- 7.5.6. Japan Epidemiology
  - 7.5.6.1. Neovascular Age-related Macular Degeneration Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Neovascular Age-related Macular Degeneration Treatment and Management
8.2. Neovascular Age-related Macular Degeneration Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Neovascular Age-related Macular Degeneration Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
- 11.2.1. Product Description
- 11.2.2. Regulatory Milestones
- 11.2.3. Other Developmental Activities
- 11.2.4. Pivotal Clinical Trials
- 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross
12.2. Drug Name: Company Name
- 12.2.1. Product Description
- 12.2.2. Other Developmental Activities
- 12.2.3. Clinical Development
- 12.2.4. Safety and Efficacy
- 12.2.5. Product Profile